COMPANY:

Caris Life Sci

"Caris Life Sciences®...has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. MI Cancer Seek is the first and only test to combine whole exome sequencing (WES) and whole transcriptome sequencing (WTS) with FDA-approved CDx indications for solid tumor profiling in both adult and pediatric patients, marking a significant advancement in precision oncology."

"Caris Life Sciences®...has published a new study in Communications Medicine, a Nature portfolio journal, demonstrating that Caris’ AI-based image analysis model has the potential to more accurately predict cancer biomarkers and patient survival than the conventional companion diagnostic (CDx) methods. By analyzing hematoxylin and eosin (H&E) images, the study demonstrated that Caris’ AI model can improve the assessment of critical cancer biomarkers and impact patient survival outcomes in breast and colorectal cancers."

"Caris Life Sciences®...recently published a study on the development and validation of Caris’ latest version of Caris GPSai™ in AACR’s Cancer Research Communications Journal. Caris GPSai is a clinically validated deep learning multi-layer AI that leverages comprehensive whole exome and whole transcriptome sequencing (WES/WTS) to significantly improve diagnostic accuracy for cancers of unknown primary (CUP) and identify patients who have potentially misdiagnosed tumors."

"The CheckMate 8HW trial reported longer progression-free survival with Ipilimumab/Nivolumab (Ipi/Nivo) compared to Nivo monotherapy, but it remains unclear if all dMMR CRC patients should be offered ipi/nivo. Here, we investigated the survival benefit of Ipi/Nivo compared to Pembrolizumab (pembro) according to MutS vs. MutL co-loss...Assessment of mutS vs. mutL status provides a novel stratification that can further refine treatment algorithms for selection of specific ICI regimens in this patient population. Legal entity responsible for the study The authors."

"Caris Life Sciences®...announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum."

"Caris Life Sciences(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung cancer (NSQ NSCLC) patients and is poised for future drug approvals....Comprehensive Molecular Profiling: Caris utilizes a multi-platform approach, including immunohistochemistry (IHC) and next-generation sequencing (NGS), to provide a detailed molecular profile of NSQ NSCLC tumors. Identification of Actionable Targets: The MET IHC testing helps identify overexpression of the MET protein, which is associated with poor prognosis and can be targeted by specific therapies."

"Caris Life Sciences®...today announced a strategic collaboration with MiBA, an innovative healthcare technology company to provide physician education and insights to accelerate research, identify and personalize treatment plans. This partnership aims to help improve patient care and advance precision medicine by supporting oncologists’ experience with Next Generation Sequencing (NGS) testing and supporting clinical research through operational optimization, BioPharma clinical trials and real-world data project identification."

"Caris Life Sciences...today announced the publication of 'Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals' in Nature Communications...the study provides a comprehensive evaluation of real-world outcomes for patients eligible for these powerful 'pan-cancer' therapies, such as pembrolizumab and larotrectinib...Key findings include: More than 20 percent of patients are candidates for a tissue-agnostic drug. Approximately five percent of patients who lacked any tumor-specific indication were found to carry a tissue-agnostic indication and became eligible for tissue-agnostic drug treatment. Tissue-agnostic therapy uptake was poor for rare indications, illustrating the need for enhanced clinical education. Current tissue-agnostic indications could potentially be expanded, as evidenced by clinical benefits in tumor types and drugs of the same class that were not investigated in the original clinical trials."

"Caris Life Sciences® (Caris)...today announced the publication of "Characterization of plasma cell-free DNA variants as of tumor- or clonal hematopoiesis-origin in 16,812 advanced cancer patients," in Clinical Cancer Research. Utilizing Caris Assure™ blood-based profiling, the study shows how CH-associated variants, which are highly prevalent in cancer patients, can often overlap with therapeutic targets. The findings underscore the importance of distinguishing CH- from tumor-derived mutations to improve diagnostic accuracy and guide appropriate cancer therapy."

"Caris Life Sciences…announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (Caris POA), will collectively present three studies at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, February 13-15, in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris’ comprehensive database to enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan and response to treatment."

"Caris Life Sciences®...today announced the presentation of data highlighting the clinical value of subtracting clonal hematopoiesis (CH) mutations from liquid biopsy profiling results to avoid incorrect treatment recommendations. Caris generated the findings, in collaboration with leading cancer centers, including those within the Caris Precision Oncology Alliance™ (Caris POA), and presented the data on November 23, 2024, at the International Society for Liquid Biopsy (ISLB) 6th Annual Congress. The study’s results demonstrate the power of the Caris Assure™ assay to identify somatic tumor, incidental CH and incidental germline variants by sequencing both the plasma and buffy coat in a single whole exome and whole transcriptome next-generation sequencing assay."

"Caris Life Sciences®...announced the U.S. Food and Drug Administration (FDA) has approved MI Cancer Seek™ for use as a companion diagnostic (CDx) to identify cancer patients who may benefit from treatment with targeted therapies. The assay includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. MI Cancer Seek is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adults and pediatric patients, ages 1-22."